Initial Combination Therapy in Type 2 Diabetes.

Authors:
Kim JY; Kim NH.

Journal:
Endocrinol Metab (Seoul)

Publication Year: 2023

DOI:
10.3803/EnM.2023.1816

PMCID:
PMC10901659

PMID:
38031401

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Endocrinol Metab (Seoul)

Abbreviation: Endocrinol Metab (Seoul)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A Contemporary Approach to the Diagnosis and Management of Adrenal Insufficiency.
Charoensri S; Auchus RJ. (2024) - Transparency Score: 2/6
Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option wit…
Yoon JH; Choi W; Park JY and 3 more (2024) - Transparency Score: 4/6
Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines.
Kim MJ; Moon JH; Lee EK and 7 more (2024) - Transparency Score: 3/6
FoxO6-Mediated TXNIP Induces Lipid Accumulation in the Liver through NLRP3 Inflammasome Activation.
Kim ME; Lee JS; Kim TW and 2 more (2024) - Transparency Score: 3/6
Hypothalamic AMP-Activated Protein Kinase as a Whole-Body Energy Sensor and Regulator.
Min SH; Song DK; Lee CH and 2 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported."

Evidence found in paper:

"This work was supported by the Korean Endocrine Society New Faculty Research Award 2018."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025